Melanotan II is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Insulin granules are a specific type of granule found in pancreatic beta cells. Insulin granules are secretory granules, which are responsible for the storage and secretion of insulin, a hormone that regulates the concentration of glucose in the bloodstream to maintain homeostasis. The release of insulin by granules is signaled by plasma glucose concentrations and the resultant influx of calcium ions in pancreatic cells, which initiate granule exocytosis. Insulin release is biphastic, as insulin is first released in the primary phase by granules closest to the plasma membrane. In the secondary phase, insulin granules are recruited from reserves deeper in the beta cell for a slower release rate. Insulin granules undergo a significant maturation process. First, precursor proinsulin molecules are synthesized in the endoplasmic reticulum and packaged in the golgi network. Insulin granules bud from the trans golgi network and are further sorted via clathrin-coated vesicle transport. After budding, insulin secretory granules are acidified, activating endoproteases PC1/3 and PC2 to convert proinsulin into insulin. The clatherin coating is released and the insulin secretory granules are transported across the cell via actin filaments and microtubules.
Campbell-Bannerman tried to keep these forces together at the head of a moderate Liberal rump, but in 1901 he delivered a speech on the government's "methods of barbarism" in South Africa that pulled him further to the left and nearly tore the party in two. The party was saved after Salisbury's retirement in 1902 when his successor, Arthur Balfour, pushed a series of unpopular initiatives such as the Education Act 1902 and Joseph Chamberlain called for a new system of protectionist tariffs. Campbell-Bannerman was able to rally the party around the traditional liberal platform of free trade and land reform and led them to the greatest election victory in their history. This would prove the last time the Liberals won a majority in their own right. Although he presided over a large majority, Sir Henry Campbell-Bannerman was overshadowed by his ministers, most notably H. H. Asquith at the Exchequer, Edward Grey at the Foreign Office, Richard Burdon Haldane at the War Office and David Lloyd George at the Board of Trade. Campbell-Bannerman retired in 1908 and died soon after. He was succeeded by Asquith, who stepped up the government's radicalism. Lloyd George succeeded Asquith at the Exchequer and was in turn succeeded at the Board of Trade by Winston Churchill, a recent defector from the Conservatives.
==== Impossibility of the "negligence" ==== According to the "Corporate Negligence" argument, workers had been cleaning out pipes with water nearby. This water was diverted due to a combination of improper maintenance, leaking and clogging, and eventually ended up in the MIC storage tank. Indian scientists also suggested that additional water might have been introduced as a "back-flow" from a defectively designed vent-gas scrubber. None of these theoretical routes of entry were ever successfully demonstrated during tests by the Central Bureau of Investigation (CBI) and UCIL engineers. A Union Carbide commissioned analysis conducted by Arthur D. Little claims that the Negligence argument was impossible for several tangible reasons:
Cannabidiol was isolated and identified from Cannabis sativa in 1940 by Roger Adams who was also the first to document the synthesis of THC (both delta-9-THC and delta-8-THC) from the acid-based cyclization of CBD in 1942. THC was first isolated from Cannabis in 1964.
A lack of economy of size: as most fine chemicals are produced in quantities of less than a few 10 tons per year in multipurpose plants, there is little or no economy of size. The reactor trains of these plants are similar throughout the industry. Regardless of the size of the companies, their main constituents, the reaction vessels, have a median size of 4–6 m3 (140–210 cubic feet). Various products are made throughout a year in campaigns. Therefore, the unit cost per m3 per hour rarely varies with the size of the company. A dichotomy between ownership and management: the company's shares are listed on stock exchanges, and their performance is scrutinized by the financial community. Postponement of a single important shipment can affect a quarterly result. In the small and mid-sized companies, the owners are typically the major shareholders, often members of the same family. Their shares are not traded publicly and fluctuations in their financial performance are more easily coped with. Complicated business processes: flexibility and responsiveness are in jeopardy. Customer complaints, for instance, are difficult to resolve in a straightforward manner. A heterogeneous portfolio of small companies, accumulated over time through M&A activities. The key functions, such as production, R&D, and M&S, are located on different sites, often in different countries. Cohabitation with other units. A comprehensive list of about 1400 fine chemical companies (including traders) can be found in the "event catalogue" of the CPhI exhibition.
Sources: en.wikipedia.org
== Diagnosis == Epidemiologically, the disorder usually develops slowly and is mainly observed in people over the age of 50. Diagnosis is made on the basis of bone marrow biopsy. Fibrosis grade 2 or 3 defines overt PMF whereas grade 0 or 1 defines prefibrotic primary myelofibrosis. A physical exam of the abdomen may reveal enlargement of the spleen, the liver, or both. Bone marrow biopsy shows fibrosis of the bone marrow. In early stages, this fibrosis is characterised by scattered linear reticulin fibres.
== Interactions == While opipramol is not a monoamine reuptake inhibitor, any irreversible MAOIs should still be discontinued at least 14 days before treatment. Opipramol can compete with other tricyclic antidepressants, beta blockers, antiarrhythmics (of class 1c), and other drugs for microsomal enzymes, which can lead to slower metabolism and higher plasma concentrations of these drugs. Co-administration of antipsychotics (e.g., haloperidol, risperidone) can increase the plasma concentration of opipramol. Barbiturates and anticonvulsants can reduce the plasma concentration of opipramol and thereby weaken its therapeutic effect.
=== Humans === Because branched chain amino acids are crucial in the formation and function of many proteins, BCATs have many responsibilities in mammalian physiology. BCATs have been found to interact with protein disulfide isomerases, a class of enzymes that regulate cellular repair and proper protein folding. The second step of branched chain amino acid metabolism (oxidative carboxylation by branched chain ketoacid dehydrogenase) stimulates insulin secretion. Loss of BCATm correlates with a loss in BCKD-stimulated insulin secretion, but has not been associated with losses in insulin secretion from other metabolic pathways. BCATc regulates the mTORC1 signaling and TCR-induced glycolytic metabolism pathways during CD4+ T cell activation. In the brain, BCATc regulates the amount of glutamate production for use as a neurotransmitter or for future γ-Aminobutyric acid (GABA) synthesis.
The ICD-11 instead distinguishes a harmful episode of use, a harmful pattern of use, and dependence. Prevention approaches with the strongest supporting evidence include family skills programs, school-based personal and social skills education, and policies that limit availability and raise price. Addiction is managed as a chronic, relapsing condition, usually combining medication, where an effective one exists, with psychological and social support. Effective medications are available for opioid, alcohol, and tobacco use disorders, but none is approved for stimulant use disorder, for which psychosocial treatment remains the mainstay. Harm reduction measures address the damage associated with continued use. Outcomes vary widely: an estimated 35–54% of people with a substance use disorder reach remission, though typically only after many years. About 163 million people worldwide were estimated to be living with a substance use disorder in 2021, most commonly alcohol use disorder, and drug use was one of only three risk factors whose age-standardized attributable burden rose between 2010 and 2023. Addiction carries substantial economic and social costs, and anthropological and structural accounts situate heavy drug use within cultural norms and unequal distributions of power.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.